In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Autolus's Nasdaq IPO nets $139.5mm

Executive Summary

Autolus Ltd. (T-cell immunotherapies for cancer) netted $139.5mm through its public offering of 8.8mm American Depositary Shares at $17 on the Nasdaq Global Exchange. (Each ADS represents one ordinary share.) The company originally intended to sell 7.8mm ADSs at a range of $15-17.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies